Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
Open Access
- 1 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 99 (6), 1241-1249
- https://doi.org/10.1007/s00277-020-04018-1
Abstract
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those resistant or intolerant to prior therapy. In the Bosutinib Trial in First-Line Chronic Myelogenous Leukemia Treatment (BFORE), bosutinib demonstrated a significantly higher major molecular response rate compared with imatinib, with maintenance of HRQoL (measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire), after 12 months of first-line treatment. We examined relationships between molecular response (MR) and HRQoL. MR values were represented by a log-reduction scale (MRLR; a continuous variable). A repeated-measures longitudinal model was used to estimate the relationships between MRLR as a predictor and each FACT-Leu domain as an outcome. Effect sizes were calculated to determine strength of effects and allow comparisons across domains. The majority of FACT-Leu domains (with the exception of social well-being and physical well-being) demonstrated a significant relationship with MRLR (p < 0.05). Our results showed variable impact of clinical improvement on different dimensions of HRQoL. For patients who achieved MR5, emotional well-being and leukemia-specific domains showed the greatest improvement, with medium differences in effect sizes, whereas social well-being and physical well-being had the weakest relationship with MR.Keywords
Funding Information
- Universitätsklinikum RWTH Aachen
This publication has 40 references indexed in Scilit:
- Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparisonSupportive Care in Cancer, 2012
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationBlood, 2011
- Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemiaLeukemia & Lymphoma, 2011
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid LeukemiaNew England Journal of Medicine, 2010
- Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-GJournal of Clinical Epidemiology, 2010
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Natural history and staging of chronic myelogenous leukemiaHematology/Oncology Clinics of North America, 2004
- Quality of Life in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia on Imatinib Versus Interferon Alfa Plus Low-Dose Cytarabine: Results From the IRIS StudyJournal of Clinical Oncology, 2003
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003